Main Article Content


We report a case of a 47-year-old male, who was referred to the clinical hepatology services at Pablo Tobón Uribe Hospital for evaluation of a jaundice syndrome. After undergoing several exams, we diagnosed hepatic hydatidosis and the patient was treated with albendazole; however, after five months of uninterrupted treatment the patient again consulted and his liver test showed marked hepatocellular damage. This time, the patient was diagnosed with drug-induced liver injury due to albendazole, based on information from the clinical record, history of drug consumption, clinical and laboratory tests improved after discontinuing the medication and after discarding other possible causes; this diagnosis was supported by the CIOMS/RUCAM scale, which showed a “likely” correlation between hepatocellular damage and drug toxicity etiology.


Ríos, D., & Restrepo, J. C. (2013). Albendazole-induced liver injury: a case report. Colombia Medica, 44(2), 118–120.

Vuitton DA. The WHO Informal Working Group on Echinococcosis. Coordinating Board of the WHO-IWGE. Parassitol. 1997; 39(4): 349-53.

Garcia HH, Evans CA, Nash TE, Takayanagui OM, White AC Jr, Botero D, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002; 15(4): 747-56.

Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitol. 2000; 121(Suppl 1): 113-32.

Singthong S, Intapan PM, Wongsaroji T, Maleewong W. Randomized comparative trial of two high-dose Albendazole regimens for uncomplicated human strongyloidiasis. Southeast Asian J Trop Med Public Health. 2006; 37(Suppl 3): 32-4.

Brunton L, Lazo JS, Parker KL. Goodman Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006.

Maartens G, Sinxadi P, Pharmacology of anthelmintics: Albendazole, Mebendazole and praziquantel. CME. 2009; 274-6.

Horton J. Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations. Curr Opin Infect Dis. 2002; 15: 599-608.

Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, et al. Acute drug-induced hepatitis caused by albendazole. J Korean Med Sci Korea South. 2008; 23(5): 903-5.

Amoruso C, Fuoti M, Miceli V, Zito E, Celano MR, De Giorgi A, et al. Acute hepatitis as a side effect of albendazole: a pediatric case. Pediatr Med Chir. 2009; 31(6): 262-4.

Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11(2): 272-6.

Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanches de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatol. 2001; 33: 123-30.

Ghabril M, Chalasani N, Bjornsson E. Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol. 2010; 26(3): 222-6.

Gil GL, Rodríguez CF, Prieto J, Sánchez RJ, Brasa C, Aguilar L, et al. Randomized controlled trial of efficacy of albendazole in intra-abdominal hydatid disease. Lancet. 1993; 342: 1269-72.

Hussain S, Malik A, Khaja AR, Dass T, Naikoo Z. Role of Albendazole in the management of hydatid cyst liver. Saudi J Gastroenterol. 2011; 17(5): 343-7.

Bildik N, Cevik A, Altintaş M, Ekinci H, Canberk M, Gülmen M. Efficacy of preoperative Albendazole use according to months in hydatid cyst of the liver. J Clin Gastroenterol. 2007; 41(3): 312-6.


Download data is not yet available.
Received 2012-02-01
Accepted 2012-11-25
Published 2013-05-31

Similar Articles

You may also start an advanced similarity search for this article.